Figure 1.
Correlation between muscle mass index and lung function.
Legend: R2 for FVC (L), 0.048, P<0.001; FVC (% predicted), 0.068, P<0.001; FEV1 (L), 0.037, P = 0.001; FEV1 (% predicted), 0.007, P = 0.181, FEV1/FVC, 0.001, P = 0.670.
Table 1.
Clinical characteristics according to sarcopenia and obesity status.
Figure 2.
Comparison of lung function according to the presence of sarcopenia and obesity (mean, 95% CI).
Legend: Values were adjusted by age, height, weight, obesity, and current smoking status. Abbreviation: absence of sarcopenia and obesity, S−O−; absence of sarcopenia and presence of obesity, S−O+; presence of sarcopenia and absence of obesity, S+O−; presence of both sarcopenia and obesity, S+O+.
Table 2.
Factors associated with advanced COPD (% FEV1<80).
Table 3.
Multivariate analysis for factors contributing to subjective exercise limitation.
Table 4.
Physical activity and activity limitation comparison between sarcopenia and obesity.
Figure 3.
Comparison of quality of life according to the presence of sarcopenia and obesity (mean, 95% CI).
Legend: Values were adjusted by age, COPD stage, sarcopenia, obesity, and current smoking status. Abbreviation: absence of sarcopenia and obesity, S−O−; absence of sarcopenia and presence of obesity, S−O+; presence of sarcopenia and absence of obesity, S+O−; presence of both sarcopenia and obesity, S+O+.